Symbiomix
develops and commercializes novel therapies for the treatment of gynecological infections and bacterial vaginosis... Read moreSymbiomix
develops and commercializes novel therapies for the treatment of gynecological infections and bacterial vaginosis... Read more
News
Oct 28, 2018
BioPortfolio
Symbiomix: Symbiomix Therapeutics LLC Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27092018 Prices from USD $250
Jul 31, 2018
BioPortfolio
Symbiomix: Symbiomix Therapeutics LLC Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 20062018 Prices from USD $250
Apr 18, 2018
BioPortfolio
Symbiomix: Symbiomix Therapeutics LLC Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14032018 Prices from USD $250
Nov 09, 2017
Business Wire
Press Release: Symbiomix : Roshini Raj, MD and Shan Boody Collaborate to Empower Women to Take Control of Their Gynecologic Health
Oct 15, 2017
USCHNews
Symbiomix: Lupin's Symbiomix acquisition looks like a step in the right direction
Oct 14, 2017
Moneycontrol
Symbiomix: This week in pharma: Sun Pharma get EIR for Dadra plant, Lupin acquires Symbiomix Therapeutics
Oct 13, 2017
Moneycontrol
Symbiomix: Lupin readies for a mega specialty drug play with $1-bn war chest
Oct 12, 2017
Moneycontrol
Symbiomix: Expect acquisitions to boost growth; several products lined up for next year: Lupin
Oct 02, 2017
PRWeb
Press Release: Symbiomix : Symbiomix Therapeutics Receives FDA Approval of Solosec (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
Sep 19, 2017
Center Watch
Symbiomix: FDA approves Symbiomix Therapeutics' Solosec for bacterial vaginosis
